Pancreatic cancer patients who benefit from personalized treatment identified

About 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature, scientists say. This sub-group of pancreatic cancer patients who possess a strong angiogenic gene signature could benefit from personalized therapies that cut off the pathways that feed the cancer's growth, they note.



from News -- ScienceDaily http://ift.tt/1wkWm1F via Karis World